Mesoblast Limited (MESO)
NASDAQ: MESO
· Real-Time Price · USD
16.22
0.36 (2.27%)
At close: Aug 15, 2025, 3:59 PM
16.25
0.18%
After-hours: Aug 15, 2025, 07:52 PM EDT
2.27% (1D)
| Bid | 14.44 |
| Market Cap | 1.84B |
| Revenue (ttm) | 5.67M |
| Net Income (ttm) | -103.35M |
| EPS (ttm) | -1.3 |
| PE Ratio (ttm) | -12.48 |
| Forward PE | -39.63 |
| Analyst | Buy |
| Ask | 16.75 |
| Volume | 218,798 |
| Avg. Volume (20D) | 239,967 |
| Open | 16.29 |
| Previous Close | 15.86 |
| Day's Range | 16.05 - 16.38 |
| 52-Week Range | 6.00 - 22.00 |
| Beta | 1.32 |
About MESO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MESO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MESO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Mesoblast Limited is scheduled to release its earnings on
Aug 28, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+11.29%
Mesoblast shares are trading higher after the comp...
Unlock content with
Pro Subscription
3 months ago
+3.55%
Mesoblast shares are trading higher after the company secured a 7-year FDA orphan-drug exclusivity for Ryoncil in steroid-refractory pediatric graft versus host disease.
3 weeks ago · https://www.proactiveinvestors.com
Mesoblast shares surge on strong Ryoncil launch, tapering off after Friday rallyShares in Mesoblast Ltd (NASDAQ:MESO, ASX:MSB) surged by nearly 38% following Friday’s successful commercial launch of its FDA-approved treatment, Ryoncil®, for steroid-refractory acute graft-versus-h...
